Lanean...
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies
The treatment of advanced gastrointestinal (GI) cancers has become increasingly molecularly driven. Molecular profiling for HER2 and PD-L1 status is standard for metastatic gastroesophageal (GEJ) cancers to predict benefits from trastuzumab (HER2-targeted therapy) and pembrolizumab (anti-PD-1 therap...
Gorde:
| Argitaratua izan da: | Cancers (Basel) |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7281439/ https://ncbi.nlm.nih.gov/pubmed/32384640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051168 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|